MedAware vs NarxCare
Both score a prescribing situation for risk and they are pointed at opposite risks, which is why comparing them is useful even though almost nobody buys them against each other. NarxCare scores the patient, using state prescription monitoring data to produce controlled substance risk visualisations that a prescriber or pharmacist sees at the moment of decision. MedAware scores the prescription, detecting orders that do not fit this patient through outlier detection over longitudinal clinical data, with independent Harvard led evaluation behind it. The asymmetry that matters is in the consequence of being wrong. A false positive from MedAware wastes a pharmacist's time. A false positive from a controlled substance risk score can mean a patient in pain is refused treatment, and neither the vendor nor the states deploying it publish the subgroup performance that would tell you how often that happens.
- It is derived from state prescription monitoring data rather than from the hospital's own record, so it sees prescriptions written elsewhere that no internal system would surface.
- It is already present in many prescribing workflows through the state programme rather than requiring a separate purchase, which is a different adoption path from any commercial product here.
- Scores and visualisations are designed for a rapid decision at the point of dispensing or prescribing rather than for retrospective review.
- The detection target is different and broader: prescriptions that do not fit the patient, caught through unsupervised outlier detection over longitudinal clinical data rather than through a score built on dispensing history.
- The evidence was produced mainly by investigators independent of the company, including a Harvard Medical School group, rather than by the vendor.
- Output is an alert to a prescriber or pharmacist who decides, with the system never acting on a medication, and its integrations are confirmed by named customers.
Side by Side
| Axis | M MedAware |
N NarxCare |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Risk scoring on controlled substance history carries a consequence that exists nowhere else in this category: a false positive is not wasted time, it is a patient refused treatment. Published analyses of widely deployed prescription risk scores have found misclassification rates high enough to matter clinically, and the scored behaviours, pharmacy counts, prescriber counts and distance travelled, track access to care at least as well as they track risk, so a patient who is poor, rural or has moved will score higher for reasons unrelated to misuse. Neither vendor publishes subgroup performance or a bias assessment, and neither publishes pricing. MedAware publishes no located security attestation or business associate terms.